Lipid metabolism is essential for normal brain function, playing critical roles in membrane structure, signal transduction, energy homeostasis, and synaptic plasticity. Lipid dysregulation is increasingly recognized as a key contributor to neurodegenerative processes in Alzheimer's disease, Parkinson's disease, and other disorders.
Key aspects of brain lipid metabolism:
- Cholesterol: Myelin formation, synaptic vesicle function, membrane rafts
- Phospholipids: Membrane structure, signaling molecules
- Sphingolipids: Ceramide, sphingosine-1-phosphate in apoptosis
- Fatty acids: Energy substrate, inflammatory mediators
flowchart TD
A[Altered Lipid Metabolism] --> B[Membrane Changes] -->
A --> C[Cholesterol Dysregulation] -->
A --> D[Fatty Acid Accumulation] -->
B --> E[Lipid Raft Alterations] -->
E --> F[Aβ Production Increase] -->
F --> G[Amyloid Pathology] -->
C --> H[APOE Effects] -->
H --> I[Impaired Aβ Clearance] -->
I --> G
D --> J[Lipid Droplet Accumulation] -->
J --> K[ER Stress] -->
K --> L[Unfolded Protein Response)
L --> M[Neuronal Death] -->
D --> N[Lipotoxicity] -->
N --> O[Mitochondrial Dysfunction)
O --> P[ROS Generation] -->
P --> M
G --> Q[Cognitive Decline] -->
M --> Q
- High brain cholesterol (70% of body total)
- Synthesized locally (cannot cross BBB)
- APOE mediates cholesterol transport
- AD risk variants affect lipid binding
- Primary membrane components
- Source of second messengers
- Altered in AD brain
- PLA2 hyperactivity linked to inflammation
- Ceramide: Pro-apoptotic, elevated in AD
- Gangliosides: Aβ interaction
- Sulfatides: Myelin maintenance
- APOE4: Impaired lipid transport, increased Aβ deposition
- Cholesterol: High levels accelerate amyloidogenesis
- Phospholipases: Increased activity, membrane damage
- Ceramide: Elevated in AD brain, promotes apoptosis
- α-Synuclein: Binds lipid membranes
- Fatty acids: Modulate aggregation
- Glucosylceramide: Increases α-synuclein toxicity
- Niemann-Pick C: Lysosomal cholesterol trafficking defect
- Krabbe: Galactocerebrosidase deficiency
- Adrenoleukodystrophy: VLCFA accumulation
Liver X Receptor activation promotes cholesterol efflux:
- T0901317: Preclinical
- RGX-104: Phase 1 trials
Acyl-CoA:cholesterol acyltransferase inhibition:
- avasimibe: Reduces Aβ production
- CP-113,818: Preclinical
- Statins: Mixed evidence for neurodegeneration
- Cyclodextrin: Cholesterol solubilization
- APOE-directed therapies: Gene editing, peptides
The study of Lipid Dysregulation In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Di Paolo G, Kim TW. (2011). Nat Rev Neurosci. 12:284-296. [PMID: 21448224]
- Vance JE. (2012). Biochim Biophys Acta. 1821:624-634. [PMID: 22179154]
- Liu JP, et al. (2010). Cell Mol Neurobiol. 30:903-914. [PMID: 20204647]
- Puglielli L, et al. (2003). Nat Rev Neurosci. 4:782-792. [PMID: 14518280]
- Michikawa M, et al. (2000). J Neurosci. 20:4495-4500. [PMID: 10844021]
- Grimm MO, et al. (2011). EMBO Mol Med. 3:583-593. [PMID: 21826761]
- Cutler RG, et al. (2004). Nat Rev Neurosci. 5:781-792. [PMID: 15380034]
- Martinez M, et al. (2014). J Alzheimers Dis. 40:S73-85. [PMID: 24577440]
- van Deursen JM. (2016). Nat Rev Drug Discov. 15:219-220. [PMID: 26960244]
- Wang H, Kulas JA, et al. (2021). Nat Neurosci. 24:1210-1221. [PMID: 34326535]
- Lane-Donovan C, Herz J. (2017). Nat Rev Neurol. 13:30-38. [PMID: 27974853]
- Wu M, et al. (2021). Prog Lipid Res. 82:101091. [PMID: 33774079]
- Hussain G, et al. (2019). Mol Neurobiol. 56:1538-1554. [PMID: 29892767]
- Liu Q, et al. (2013). J Biol Chem. 288:20809-20822. [PMID: 23687297]
- Wood WG, et al. (2010). J Neurochem. 115:1-17. [PMID: 20618533]
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 45%